1-(2,4-二氟苯基)哌嗪 | 115761-79-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2,4-二氟苯基)哌嗪
• 中文别名: 二氟苯基哌嗪
• 英文名称: 1-(2,4-difluoro-phenyl)piperazine
• 英文别名: 2,4-difluorophenylpiperazine；1-(2,4-Difluorophenyl)piperazine
• CAS: 115761-79-0
• 化学式: C₁₀H₁₂F₂N₂
• 分子量: 198.215
• InChiKey: CMCSPBOWEYUGHB-UHFFFAOYSA-N

物化性质

• 熔点：
  74-76
• 沸点：
  100 °C (0.37505 mmHg)
• 密度：
  1.192±0.06 g/cm3(Predicted)
• 闪点：
  108-111°C/0.2mm
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）
• 稳定性/保质期：
  如果按照规定使用和储存，则不会发生分解，目前没有已知的危险反应。请避免与氧化物和空气接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R23/24/25,R34
• 海关编码：
  2933599090
• 包装等级：
  II
• 危险类别：
  6.1
• 危险品运输编号：
  UN2928
• 储存条件：
  请将贮藏器保持密封状态，并存放在阴凉干燥处。同时，确保工作环境中具有良好的通风或排气设施。

SDS

Name:	1-(2 4-Difluorophenyl)piperazine 98% Material Safety Data Sheet
Synonym:
CAS:	115761-79-0

Section 1 - Chemical Product MSDS Name:1-(2 4-Difluorophenyl)piperazine 98% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
115761-79-0	1-(2,4-Difluorophenyl)piperazine	98%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 115761-79-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 100 deg C @0.5mbar
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12F2N2
Molecular Weight: 198.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, acid chlorides, acid anhydrides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 115761-79-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2,4-Difluorophenyl)piperazine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 115761-79-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 115761-79-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 115761-79-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2,4-二氟苯基)哌嗪 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 20.0h， 生成 N-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]-2-oxoethyl]isoquinoline-5-sulfonamide
  参考文献：
  名称：

  From Tyrosine to Glycine:  Synthesis and Biological Activity of Potent Antagonists of the Purinergic P2X₇ Receptor

  摘要：

  The characterization of the native and recombinant P2X(7) receptor continues to be hindered by the lack of specific and subtype-selective antagonists with a "druglike" profile. However, a tyrosine derivative named KN-62 exhibits selective P2X(7) receptor-blocking properties. As a molecular simplification of KN-62, the present study was designed to evaluate the functional antagonistic properties of a novel series of glycine derivatives characterized by the presence of different phenyl-substituted piperazine moieties. Antagonistic activity of these glycine derivatives was tested on HEK293 cells transfected with the human P2X(7) receptor. The most potent P2X(7) receptor antagonist identified in this study (compound 4g) contains an o-fluorine substituent on the phenylpiperazine moiety and had an IC50 of 12.1 nM. The biological responses investigated were ATP-dependent Ca2+ influx across the plasma membrane and ethidium bromide uptake.

  DOI：

  10.1021/jm070443e
• 作为产物：
  描述：

  tert-butyl 4-(2,4-difluorophenyl)piperazine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 1-(2,4-二氟苯基)哌嗪
  参考文献：
  名称：

  [EN] TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS
  [FR] AGENTS DE DÉGRADATION TRICYCLIQUES D'IKAROS ET D'AIOLOS

  摘要：

  三环脑蛋白结合剂通过泛素蛋白酶体途径降解Ikaros或Aiolos以用于治疗应用的描述。

  公开号：

  WO2020210630A1
• 作为试剂：
  描述：

  2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl 4-methylbenzenesulfonate 、 1-(2,4-二氟苯基)哌嗪 在 1-(2,4-二氟苯基)哌嗪 作用下， 生成 SCH 412348
  参考文献：
  名称：

  Adenosine A2a receptor antagonists

  摘要：

  具有结构式I或其药物可接受的盐，其中R是可选取代的苯基，环烯基或杂环基；X是烷基或-C（O）CH2-；Y是-N（R2）CH2CH2N（R3）-，-OCH2CH2N（R2）-，-O-，-S-，-CH2S-，-（CH2）2-NH-或可选取代的m和n为2-3，Q为氮或可选取代的碳；Z是可选取代的苯基，苯基烷基或杂环基，二苯甲基，R6-C（O）-，R6-SO2-，R6-OC（O）-，R7-N（R8）-C（O）-，R7-N（R8）-C（S）-，苯基-CH（OH）-或苯基-C（═NOR2）-；或当Q为CH时，为苯胺基或吡啶基氨基；或Z和Y一起为取代的哌啶基或取代的苯基；以及R2，R3，R6，R7和R8在说明书中所定义的，它们在单独使用或与其他治疗帕金森病的药物联合使用中用于治疗帕金森病的用途以及包含它们的制药组合物；还披露了用于制备结构式I化合物的有用中间体的制备过程。

  公开号：

  US07067655B2

文献信息

• [EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION
  申请人：INTERVET INT BV

  公开号：WO2010115688A1

  公开（公告）日：2010-10-14

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  这项发明涉及一般用作驱虫剂或作为制备驱虫剂的中间体的化合物和盐。这项发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，以及将这些化合物和盐用于需要治疗的动物的治疗方法。
• [EN] NOVEL AGENTS TARGETING CYP51<br/>[FR] NOUVEAUX AGENTS CIBLANT CYP51
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015048306A1

  公开（公告）日：2015-04-02

  The invention provides inhibitors of a sterol C14-demethylase, a new series of 4- aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) developed using structure-based drug design as well as structure -property relationship (SPR) analyses. The screening hit starting point, LP 10 (KD < 42 nM; EC50 of 0.65 μΜ), has been optimized to give the potential leads that have low nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts. Many of the optimized compounds have improved microsome stability, and most are selective against the T. cruzi CYP51 relative to human CYPs 1A2, 2D6 and 3A4 (<50% inhibition at 1 μΜ). A rationale for the improvement of microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of several compounds of the invention with the T. brucei CYP51 (TbCYP51) ortholog has been characterized by x-ray structure analysis. Orally active compounds and their cyclodextrin complexes have been shown to be effective against Chagas-infected mice.

  该发明提供了一种甾醇C14-去甲基酶的抑制剂，这是一种新系列基于4-氨基吡啶的首选抑制剂，通过基于结构的药物设计以及结构-性质关系（SPR）分析来瞄准Trypanosoma cruzi CYP51（TcCYP51）而开发的。筛选起始点LP 10（KD < 42 nM；EC50为0.65 μΜ）已经经过优化，产生了具有低纳摩尔级别结合亲和力和对在人类肌细胞培养的T. cruzi游离体的显著活性的潜在首选抑制剂。许多经过优化的化合物具有改善的微粒体稳定性，大多数相对于人类CYPs 1A2、2D6和3A4对T. cruzi CYP51具有选择性（在1 μΜ下<50%的抑制）。提出了改善微粒体稳定性和抑制剂对人类代谢CYP酶的选择性的理由。此外，通过X射线结构分析表征了该发明的几种化合物与T. brucei CYP51（TbCYP51）同源物的结合方式。口服活性化合物及其环糊精复合物已被证明对克氏病感染的小鼠有效。
• [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20030191130A1

  公开（公告）日：2003-10-09

  Compounds having the structural formula I 1 wherein: n is 0, 1, 2 or 3; A is C(R 1 ) or N; R 1 and R 1a are H, (C 1 -C 6 )-alkyl, halo, CN or —CF 3 ; X is —C(O)—, —O—, —SO 0-2 —, or optionally substituted methylene, imino, arylene or heteroaryldiyl; Y is —O—, —SO 0-2 —, or optionally substituted arylene, heteroaryldiyl, or nitrogen-containing heterocycloalkyl, or with certain provisos, a bond; R is optionally substituted-aryl or heteroaryl; and R 2 is optionally substituted aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R 2 —Y is a fused piperidinyl, substituted piperazinyl or substituted piperidinyl; their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  具有结构式I的化合物 其中： n为0、1、2或3； A为C(R1)或N； R1和R1a为H、(C1-C6)-烷基、卤素、CN或—CF3； X为—C(O)—、—O—、—SO0-2—，或者可选择地取代的亚甲基、亚胺基、芳基或杂芳基二基； Y为—O—、—SO0-2—，或者可选择地取代的芳基、杂芳基，或含氮杂环烷基，或在一定条件下，为键； R为可选择地取代的芳基或杂芳基；和 R2为可选择地取代的芳基、杂芳基、芳基烷基或杂芳基烷基；或R2—Y为融合哌啶基、取代哌嗪基或取代哌啶基； 它们在帕金森病的治疗中的使用，单独或与其他治疗帕金森病的药剂联合使用，包括它们的药物组合物和包含这些组合物成分的套装。
• Biological evaluation of synthesised thiazolidinedione derivatives for anti-diabetic activity on STZ caused diabetes in rats
  作者：Geetha B、Swarnalatha G、Subba Reddy GV

  DOI：10.26452/ijrps.v10i2.379

  日期：——

  Diabetes Mellitus is the most common disease that poses a challenge to human health due to its secondary complications and resistance. Therefore, an attempt was made to synthesize novel compounds from thiazolidinedione moiety to treat the disease effectively and target diabetic complications. The synthesized compounds were tested for their physical parameters and characterised using NMR and IR spectra. They were also evaluated for STZ induced anti-diabetic activity in albino rats. The Compounds P5, II A8 and A9 were found effective in comparison with a standard drug, Pioglitazone. The other compounds were also effective but a reduction in activity is seen might be due to the inefficient binding to the PPAR receptors.

  糖尿病是最常见的疾病之一，由于其继发并发症和耐药性，对人类健康构成挑战。因此，尝试从噻唑烷二酮结构合成新化合物，以有效治疗该疾病并针对糖尿病并发症。合成的化合物经过物理参数测试，并使用NMR和IR光谱进行表征。它们还在雌鼠中评估了STZ诱导的抗糖尿病活性。与标准药物吡格列酮相比，化合物P5、II A8和A9表现出良好的效果。其他化合物也有效，但活性降低可能是由于与PPAR受体的结合不足。
• Chrysin-piperazine conjugates as antioxidant and anticancer agents
  作者：Rahul V. Patel、Bhupendra Mistry、Riyaz Syed、Anuj K. Rathi、Yoo-Jung Lee、Jung-Suk Sung、Han-Seung Shinf、Young-Soo Keum

  DOI：10.1016/j.ejps.2016.02.011

  日期：2016.6

  bone marrow derived mesenchymal stem cells (hBM-MSCs). Overall, 7a-w indicated remarkable antioxidant power in scavenging DPPH· and ABTS·+, particularly analogs 7f, 7j, 7k, 7l, 7n, 7q, 7v, 7w have shown promising free radical scavenging activity. Analogs 7j and 7o are identified to be highly active candidates against HeLa and CaSki cell lines, whereas 7h and 7l along with 7j proved to be very sensitive

  用1,4-二溴丁烷合成7-（4-溴丁氧基）-5-羟基-2-苯基-4H-铬-4-酮中间体处理ry素促进了ry素与多种哌嗪基团的结合，这些via嗪基团通过反应而装备在二甘醇单甲醚溶剂中用双（2-氯乙基）胺盐酸盐制得相应的胺。除了使用SRB分析评估宫颈癌癌细胞系（HeLa和CaSki）和卵巢癌细胞系SK-OV-3的体外抗癌功效外，还通过DPPH和ABTS生物测定法对制成品的自由基清除潜力进行了体外分析。 。可接受的7a-w毒性使用Madin-Darby犬肾（MDCK）细胞系进行检查。另外，使用人骨髓来源的间充质干细胞（hBM-MSC）检查了所提供化合物的细胞毒性性质。总的来说，7a-w显示出清除DPPH ·和ABTS ·+的显着抗氧化能力，尤其是类似物7f，7j，7k，7l，7n，7q，7v，7w具有清除自由基的活性。已确定类似物7j和7o是针对HeLa和CaSki细胞系的高活性候选物，而7h和